How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation

[1]  D. Colquhoun.  The False Positive Risk: A Proposal Concerning What to Do About p-Values , 2018, The American Statistician.

[2]  D. Trafimow,et al.  Measuring the Strength of the Evidence , 2018, Biomedical Journal of Scientific & Technical Research.

[3]  Jamie K. Scott,et al.  iReceptor: A platform for querying and analyzing antibody/B‐cell and T‐cell receptor repertoire data across federated repositories , 2018, Immunological reviews.

[4]  J. Ioannidis.  The Proposal to Lower P Value Thresholds to .005. , 2018, JAMA.

[5]  J. Kochenderfer,et al.  Chimeric antigen receptor T-cell therapies for lymphoma , 2018, Nature Reviews Clinical Oncology.

[6]  Anthony J. Hickey,et al.  Reproducibility, sharing and progress in nanomaterial databases. , 2017, Nature nanotechnology.

[7]  David Colquhoun,et al.  The reproducibility of research and the misinterpretation of p-values , 2017, bioRxiv.

[8]  F. Harrell,et al.  Modeling continuous response variables using ordinal regression , 2017, Statistics in medicine.

[9]  L. Vallier,et al.  Variability of human pluripotent stem cell lines. , 2017, Current opinion in genetics & development.

[10]  H. Abken,et al.  Most Do, but Some Do Not: CD4+CD25− T Cells, but Not CD4+CD25+ Treg Cells, Are Cytolytic When Redirected by a Chimeric Antigen Receptor (CAR) , 2017, Cancers.

[11]  Monica Driscoll,et al.  A long journey to reproducible results , 2017, Nature.

[12]  He Huang,et al.  Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia , 2017, Journal of Hematology & Oncology.

[13]  V. Chekhonin,et al.  Luciferase Expression Allows Bioluminescence Imaging But Imposes Limitations on the Orthotopic Mouse (4T1) Model of Breast Cancer , 2017, Scientific Reports.

[14]  A. Trounson.  Potential Pitfall of Pluripotent Stem Cells , 2017, The New England journal of medicine.

[15]  Satoshi Morita,et al.  Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model , 2017, Nature.

[16]  A. Dickson,et al.  Preservation and stability of cell therapy products: recommendations from an expert workshop. , 2017, Regenerative medicine.

[17]  Eduardo D Sontag,et al.  Evaluating optimal therapy robustness by virtual expansion of a sample population, with a case study in cancer immunotherapy , 2017, Proceedings of the National Academy of Sciences.

[18]  C. Piccinato,et al.  Intrinsic Variability Present in Wharton's Jelly Mesenchymal Stem Cells and T Cell Responses May Impact Cell Therapy , 2017, Stem cells international.

[19]  G. Pellegrini,et al.  Cultivated limbal epithelial transplantation. , 2017, Current opinion in ophthalmology.

[20]  B. Dropulić.  Reference Standards for Gene and Cell Therapy Products. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  David R Mandel,et al.  Can cancer researchers accurately judge whether preclinical reports will reproduce? , 2017, PLoS biology.

[22]  John P A Ioannidis,et al.  The Reproducibility Wars: Successful, Unsuccessful, Uninterpretable, Exact, Conceptual, Triangulated, Contested Replication. , 2017, Clinical chemistry.

[23]  R. Handsaker,et al.  Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations , 2017, Nature.

[24]  S. Nikiforow,et al.  The Why, what, and How of the New FACT standards for immune effector cells , 2017, Journal of Immunotherapy for Cancer.

[25]  J. Ioannidis.  Acknowledging and Overcoming Nonreproducibility in Basic and Preclinical Research. , 2017, JAMA.

[26]  J. Ioannidis,et al.  Empirical assessment of published effect sizes and power in the recent cognitive neuroscience and psychology literature , 2017, PLoS biology.

[27]  S. Temple,et al.  Lessons Learned from Pioneering Neural Stem Cell Studies , 2017, Stem cell reports.

[28]  Wen Jiang,et al.  Designing nanomedicine for immuno-oncology , 2017, Nature Biomedical Engineering.

[29]  Wen Jiang,et al.  Breaking Down the Barriers to Precision Cancer Nanomedicine. , 2017, Trends in biotechnology.

[30]  Brian A. Nosek,et al.  Making sense of replications , 2017, eLife.

[31]  Thomas Yu,et al.  Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. , 2017, The Lancet. Oncology.

[32]  P. Kantoff,et al.  Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.

[33]  Christopher D. Chambers,et al.  Redefine statistical significance , 2017, Nature Human Behaviour.

[34]  J. Ioannidis,et al.  When Null Hypothesis Significance Testing Is Unsuitable for Research: A Reassessment , 2016, bioRxiv.

[35]  Yolanda Gil,et al.  Enhancing reproducibility for computational methods , 2016, Science.

[36]  L. Laurent,et al.  Neural Stem Cells Derived from Human Parthenogenetic Stem Cells Engraft and Promote Recovery in a Nonhuman Primate Model of Parkinson's Disease , 2016, Cell transplantation.

[37]  Sumona Sarkar,et al.  Defining quality attributes to enable measurement assurance for cell therapy products. , 2016, Cytotherapy.

[38]  B. Levine,et al.  Engineered T cells: the promise and challenges of cancer immunotherapy , 2016, Nature Reviews Cancer.

[39]  S. Nelander,et al.  Origin of the U87MG glioma cell line: Good news and bad news , 2016, Science Translational Medicine.

[40]  Anne L Plant,et al.  Comparability: manufacturing, characterization and controls, report of a UK Regenerative Medicine Platform Pluripotent Stem Cell Platform Workshop, Trinity Hall, Cambridge, 14–15 September 2015 , 2016, Regenerative medicine.

[41]  J. Kochenderfer,et al.  Toxicities of chimeric antigen receptor T cells: recognition and management. , 2016, Blood.

[42]  Hans Clevers,et al.  Modeling Development and Disease with Organoids , 2016, Cell.

[43]  M. Baker.  1,500 scientists lift the lid on reproducibility , 2016, Nature.

[44]  S. Goodman,et al.  Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations , 2016, European Journal of Epidemiology.

[45]  David Moher,et al.  Academic criteria for appointment, promotion and rewards in medical research: where's the evidence? , 2016, European journal of clinical investigation.

[46]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[47]  N. Lazar,et al.  The ASA Statement on p-Values: Context, Process, and Purpose , 2016 .

[48]  T. Bliss,et al.  High-Resolution Microfluidic Single-Cell Transcriptional Profiling Reveals Clinically Relevant Subtypes among Human Stem Cell Populations Commonly Utilized in Cell-Based Therapies , 2016, Front. Neurol..

[49]  A. Björklund,et al.  Are Stem Cell-Based Therapies for Parkinson’s Disease Ready for the Clinic in 2016? , 2016, Journal of Parkinson's disease.

[50]  C. Barranco.  Autoimmunity: Nanomedicine, meet autoimmune disease , 2016, Nature Reviews Rheumatology.

[51]  Joshua A. Jackman,et al.  Nanomedicine for Infectious Disease Applications: Innovation towards Broad-Spectrum Treatment of Viral Infections. , 2016, Small.

[52]  A. Moore,et al.  Expanding antigen-specific regulatory networks to treat autoimmunity , 2016, Nature.

[53]  P. Thokala,et al.  Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal—An Evidence Review Group Perspective , 2016, PharmacoEconomics.

[54]  John P. A. Ioannidis,et al.  p-Curve and p-Hacking in Observational Research , 2016, PloS one.

[55]  David B. Allison,et al.  Reproducibility: A tragedy of errors , 2016, Nature.

[56]  Matthew A. Bochenek,et al.  Long term Glycemic Control Using Polymer Encapsulated, Human Stem-Cell Derived β-cells in Immune Competent mice , 2016, Nature Medicine.

[57]  S. Nelander,et al.  Origin of the U 87 MG glioma cell line : Good news and bad news , 2016 .

[58]  Kay Dickersin,et al.  Are manufacturers sharing data as promised? , 2015, BMJ : British Medical Journal.

[59]  M. Toumi,et al.  Sipuleucel-T (Provenge®)—Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention , 2015, BioDrugs.

[60]  Mauro Ferrari,et al.  Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.

[61]  S. Veresoglou.  P hacking in biology: An open secret , 2015, Proceedings of the National Academy of Sciences.

[62]  Arturo Casadevall,et al.  Increasing disparities between resource inputs and outcomes, as measured by certain health deliverables, in biomedical research , 2015, Proceedings of the National Academy of Sciences.

[63]  Alan Trounson,et al.  Stem Cell Therapies in Clinical Trials: Progress and Challenges. , 2015, Cell stem cell.

[64]  Brian A. Nosek,et al.  Promoting an open research culture , 2015, Science.

[65]  T. Schulz.  Concise Review: Manufacturing of Pancreatic Endoderm Cells for Clinical Trials in Type 1 Diabetes , 2015, Stem cells translational medicine.

[66]  I. Cockburn,et al.  The Economics of Reproducibility in Preclinical Research , 2015, PLoS biology.

[67]  P. Thokala,et al.  Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective , 2015, PharmacoEconomics.

[68]  Pia Rotshtein,et al.  Registered Reports: Realigning incentives in scientific publishing , 2015, Cortex.

[69]  D. Huh,et al.  Organs-on-chips at the frontiers of drug discovery , 2015, Nature Reviews Drug Discovery.

[70]  J. Ioannidis,et al.  Reproducibility in Science: Improving the Standard for Basic and Preclinical Research , 2015, Circulation research.

[71]  D. Geynisman,et al.  Economic evaluation of therapeutic cancer vaccines and immunotherapy: A systematic review , 2014, Human vaccines & immunotherapeutics.

[72]  P. Bianco.  "Mesenchymal" stem cells. , 2014, Annual review of cell and developmental biology.

[73]  J. Hay,et al.  Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[74]  John P. A. Ioannidis,et al.  Assessing value in biomedical research: the PQRST of appraisal and reward. , 2014, JAMA.

[75]  Stefanie Dimmeler,et al.  Translational strategies and challenges in regenerative medicine , 2014, Nature Medicine.

[76]  Ulrich Dirnagl,et al.  Distinguishing between Exploratory and Confirmatory Preclinical Research Will Improve Translation , 2014, PLoS biology.

[77]  A. Palucka,et al.  Development and function of human innate immune cells in a humanized mouse model , 2014, Nature Biotechnology.

[78]  R. Tibshirani,et al.  Increasing value and reducing waste in research design, conduct, and analysis , 2014, The Lancet.

[79]  Scott C. Brown,et al.  Particle size distributions by transmission electron microscopy: an interlaboratory comparison case study , 2013, Metrologia.

[80]  Mina Bissell,et al.  Reproducibility: The risks of the replication drive , 2013, Nature.

[81]  E. A. Sykes,et al.  Tumour-on-a-chip provides an optical window into nanoparticle tissue transport , 2013, Nature Communications.

[82]  J. Grimshaw,et al.  Threats to Validity in the Design and Conduct of Preclinical Efficacy Studies: A Systematic Review of Guidelines for In Vivo Animal Experiments , 2013, PLoS medicine.

[83]  J. Ioannidis,et al.  Evaluation of Excess Significance Bias in Animal Studies of Neurological Diseases , 2013, PLoS biology.

[84]  Jing Xu,et al.  Future of the particle replication in nonwetting templates (PRINT) technology. , 2013, Angewandte Chemie.

[85]  Eleanor H. Simpson,et al.  Faculty Opinions recommendation of Power failure: why small sample size undermines the reliability of neuroscience. , 2013 .

[86]  Ulrich Dirnagl,et al.  A Concerted Appeal for International Cooperation in Preclinical Stroke Research , 2013, Stroke.

[87]  Brian A. Nosek,et al.  Power failure: why small sample size undermines the reliability of neuroscience , 2013, Nature Reviews Neuroscience.

[88]  Dennis E Discher,et al.  Minimal " Self " Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles References and Notes , 2022 .

[89]  Philip M. Kelly,et al.  Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.

[90]  J. Masters.  Cell-line authentication: End the scandal of false cell lines , 2012, Nature.

[91]  A. Burt,et al.  Quality really matters: the need to improve specimen quality in biomedical research , 2012, The Journal of pathology.

[92]  Marco P Monopoli,et al.  Biomolecular coronas provide the biological identity of nanosized materials. , 2012, Nature nanotechnology.

[93]  P. Hall,et al.  Quality really matters: the need to improve specimen quality in biomedical research , 2012, Histopathology.

[94]  Chris Mason,et al.  What Is the Greatest Regulatory Challenge in the Translation of Biomaterials to the Clinic? , 2012, Science Translational Medicine.

[95]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[96]  Brendan Prideaux,et al.  Mass spectrometry imaging for drug distribution studies. , 2012, Journal of proteomics.

[97]  Warren C W Chan,et al.  The effect of nanoparticle size, shape, and surface chemistry on biological systems. , 2012, Annual review of biomedical engineering.

[98]  C. Begley,et al.  Drug development: Raise standards for preclinical cancer research , 2012, Nature.

[99]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[100]  O. Steward,et al.  Replication and reproducibility in spinal cord injury research , 2012, Experimental Neurology.

[101]  Andrew Emili,et al.  Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. , 2012, Journal of the American Chemical Society.

[102]  A. Trounson,et al.  The Alpha Stem Cell Clinic: A Model for Evaluating and Delivering Stem Cell‐Based Therapies , 2012, Stem cells translational medicine.

[103]  I. Weissman,et al.  The Safety of Embryonic Stem Cell Therapy Relies on Teratoma Removal , 2012, Oncotarget.

[104]  C. Glenn Begley,et al.  Raise standards for preclinical cancer research , 2012 .

[105]  D. Surmeier,et al.  Floor plate-derived dopamine neurons from hESCs efficiently engraft in animal models of PD , 2011, Nature.

[106]  D. Surmeier,et al.  Floor plate-derived dopamine neurons from hESCs efficiently engraft in animal models of PD , 2016 .

[107]  S. Manohar,et al.  Application of plasma spectrometry for the analysis of engineered nanoparticles in suspensions and products , 2011 .

[108]  F. Prinz,et al.  Believe it or not: how much can we rely on published data on potential drug targets? , 2011, Nature Reviews Drug Discovery.

[109]  Kenneth R. Hess,et al.  Statistical design considerations in animal studies published recently in cancer research. , 2011, Cancer research.

[110]  Haiying Zou,et al.  Tumor suppressor gene alterations of spontaneously malignant transformed cells from human embryonic muscle in vitro. , 2010, Oncology reports.

[111]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[112]  D. Ingber,et al.  Reconstituting Organ-Level Lung Functions on a Chip , 2010, Science.

[113]  D. Moher,et al.  A catalogue of reporting guidelines for health research , 2010, European journal of clinical investigation.

[114]  I. Cuthill,et al.  Survey of the Quality of Experimental Design, Statistical Analysis and Reporting of Research Using Animals , 2009, PloS one.

[115]  P. Schellhammer,et al.  Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer , 2009, Cancer.

[116]  Mark Bernstein,et al.  Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. , 2009, Cell stem cell.

[117]  D. Fanelli.  How Many Scientists Fabricate and Falsify Research? A Systematic Review and Meta-Analysis of Survey Data , 2009, PloS one.

[118]  J. Wilson,et al.  Identification of the murine firefly luciferase-specific CD8 T-cell epitopes , 2009, Gene Therapy.

[119]  John M Lambert,et al.  Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.

[120]  Robert Langer,et al.  Microfluidic platform for controlled synthesis of polymeric nanoparticles. , 2008, Nano letters.

[121]  M. Birkner,et al.  A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+ breast cancer (BC) , 2008 .

[122]  Warren C W Chan,et al.  Nanoparticle-mediated cellular response is size-dependent. , 2008, Nature nanotechnology.

[123]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[124]  R. Lutz,et al.  Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. , 2006, Cancer research.

[125]  S. Goodman.  Introduction to Bayesian methods I: measuring the strength of evidence , 2005, Clinical trials.

[126]  Joseph M DeSimone,et al.  Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. , 2005, Journal of the American Chemical Society.

[127]  Ginger M. Denison,et al.  High-resolution soft lithography: enabling materials for nanotechnologies. , 2004, Angewandte Chemie.

[128]  Irving L Weissman,et al.  Plasticity of Adult Stem Cells , 2004, Cell.

[129]  John P A Ioannidis,et al.  Translation of highly promising basic science research into clinical applications. , 2003, The American journal of medicine.

[130]  Rose Mary Carroll-Johnson,et al.  The good news and the bad news. , 2002, Nursing diagnosis : ND : the official journal of the North American Nursing Diagnosis Association.

[131]  B. Foster,et al.  Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. , 2000, Cancer research.

[132]  R Ogden,et al.  An open secret. , 1997, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[133]  Helmut L Karcher,et al.  The tragedy of errors , 1996 .

[134]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[135]  E. Gilboa,et al.  Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. , 1994, Cancer research.

[136]  Louette R. Johnson Lutjens.  Research , 2006 .

[137]  Shigeru Tsuchiya,et al.  Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1) , 1980, International journal of cancer.

[138]  J. Oppenheimer,et al.  A Reassessment , 1979 .

[139]  C. Pochedly.  Recognition and Management , 1971 .